Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADAP | US
0.08
8.72%
Healthcare
Biotechnology
30/06/2024
04/10/2024
0.95
0.90
0.96
0.89
Adaptimmune Therapeutics plc a clinical-stage biopharmaceutical company provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck and urothelial cancers. The company has strategic collaboration and license agreement with Genentech Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon the United Kingdom.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
77.5%1 month
58.6%3 months
85.4%6 months
84.3%-
-
2.60
0.49
0.15
-1.71
0.58
0.11
-72.88M
243.21M
243.21M
-
53.58
-
2.40K
-65.04
5.78
4.11
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.16
Range1M
0.34
Range3M
0.61
Rel. volume
0.71
Price X volume
694.41K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Nanobiotix S.A | NBTX | Biotechnology | 5.19 | 246.03M | 0.00% | n/a | -2742.14% |
Nektar Therapeutics | NKTR | Biotechnology | 1.32 | 242.98M | -0.75% | n/a | 275.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.71 | 0.76 | Cheaper |
Ent. to Revenue | 0.58 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.60 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 85.44 | 74.67 | Par |
Debt to Equity | 0.49 | -1.82 | Expensive |
Debt to Assets | 0.15 | 0.26 | Cheaper |
Market Cap | 243.21M | 3.73B | Emerging |